We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An Indian court has dismissed Novartis’ petition challenging a section of the country’s patent law, the company announced Aug. 6. Humanitarian groups say the court’s decision protects generic manufacturing in India as well as the ability of Indian companies to export generic drugs.